Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA accepted Anaphylm NDA resubmission as complete, advancing the product into formal regulatory review.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA accepted Anaphylm NDA resubmission as complete, advancing the product into formal regulatory review
- PDUFA goal date set for March 16, 2027, creating a defined approval catalyst
- Anaphylm targets Type I allergic reactions, including anaphylaxis, expanding Aquestive’s commercial opportunity upon approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.